



1614

TRANSMITTAL LETTER
(General - Patent Pending)Docket No.
3479/US

In Re Application Of: Rebanta Bandyopadhyay et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
09/849,683	May 4, 2001	Dwayne C. Jones	26648	1614	8928


Title: **METHOD OF USING COX-2 INHIBITORS IN THE TREATMENT AND PREVENTION OF OCULAR COX-2 MEDIATED DISORDERS**COMMISSIONER FOR PATENTS:


Transmitted herewith is:

Amendment Transmittal; Amendment and Response to Office Action; Itemized Postcard.




in the above identified application.

- ☒ No additional fee is required.
- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. **19-1025** as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.
SignatureDated: **October 25, 2004****Philip B. Polster, II, Reg. No. 43,864**
Pharmacia Corporation of Pfizer Inc.
P.O. Box 1027
Chesterfield, Missouri 63006
314.274.9094

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on October 25, 2004 (Date).
 Signature of Person Mailing Correspondence
Linda K. Cooper Typed or Printed Name of Person Mailing Correspondence

cc:

AMENDMENT TRANSMITTAL LETTER (Large Entity)					Docket No. 3479/US	
Applicant(s): Rebanta Bandyopadhyay et al.						
Application No. 09/849,683	Filing Date May 4, 2001	Examiner Dwayne C. Jones	Customer No. 26648	Group Art Unit 1614	Confirmation No. 8928	
Invention: METHOD OF USING COX-2 INHIBITORS IN THE TREATMENT AND PREVENTION OF OCULAR COX-2 MEDIATED DISORDERS						
 COMMISSIONER FOR PATENTS:						
Transmitted herewith is an amendment in the above-identified application.						
The fee has been calculated and is transmitted as shown below.						
CLAIMS AS AMENDED						
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE	
TOTAL CLAIMS	12 -	39 =	0 x	\$18.00	\$0.00	
INDEP. CLAIMS	1 -	11 =	0 x	\$88.00	\$0.00	
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00	
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00	
<input checked="" type="checkbox"/> No additional fee is required for amendment. <input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ <input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account 19-1025 <input type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17. <input type="checkbox"/> Payment by credit card. Form PTO-2038.						
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.						
 Signature			Dated: October 25, 2004			
Philip B. Polster, II, Reg. No. 43,864 Pharmacia Corporation of Pfizer Inc. P.O. Box 1027 Chesterfield, Missouri 63006 314.274.9094			<div style="border: 1px solid black; padding: 5px;"> <p>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on</p> <p style="text-align: center;"><u>October 25, 2004</u></p> <p style="text-align: center;">(Date)</p> <p style="text-align: center;">  Signature of Person Mailing Correspondence </p> <p style="text-align: center;">Linda K. Cooper</p> <p style="text-align: center;">Typed or Printed Name of Person Mailing Correspondence</p> </div>			
CC:						



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: R. Bandyopadhyay) GROUP ART UNIT: 1614
SERIAL NO.: 09/849,683) CONFIRMATION NO.: 8928
EXAMINER: Dwayne C. Jones) ATTORNEY DOCKET 3479/US
FILED: 05/04/2001) NO.:
TITLE: METHOD OF USING COX-2 INHIBITORS IN THE TREATMENT
AND PREVENTION OF OCULAR COX-2 MEDIATED DISORDERS

CERTIFICATE OF MAILING

I hereby certify that this communication and any recited enclosures are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on October 25, 2004.


Linda K. Cooper

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT AND RESPONSE TO OFFICE ACTION

Sir:

This letter is in response to the Office Action of July 29, 2004, having a Shortened Statutory Period for Response that is set to expire on October 29, 2004.

The Applicants believe that this response is timely filed, however, please charge any appropriate fees to Deposit Account No 19-1025. Please amend the above-identified application as follows:

Amendments to the Claims are reflected in the listing of claims that begins on page 3 of this paper.

Remarks/Arguments begin on page 6 of this paper.